193 related articles for article (PubMed ID: 30357465)
1. [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
Kastl G
Ophthalmologe; 2019 Aug; 116(8):785-788. PubMed ID: 30357465
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
de la Cruz-Merino L; Di Guardo L; Grob JJ; Venosa A; Larkin J; McArthur GA; Ribas A; Ascierto PA; Evans JTR; Gomez-Escobar A; Barteselli G; Eng S; Hsu JJ; Uyei A; Dréno B
J Transl Med; 2017 Jun; 15(1):146. PubMed ID: 28646893
[TBL] [Abstract][Full Text] [Related]
3. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
[TBL] [Abstract][Full Text] [Related]
5. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Dummer R; Queirolo P; Abajo Guijarro AM; Hu Y; Wang D; de Azevedo SJ; Robert C; Ascierto PA; Chiarion-Sileni V; Pronzato P; Spagnolo F; Mujika Eizmendi K; Liszkay G; de la Cruz Merino L; Tawbi H
Lancet Oncol; 2022 Sep; 23(9):1145-1155. PubMed ID: 35940183
[TBL] [Abstract][Full Text] [Related]
7. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
Keating GM
Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
[TBL] [Abstract][Full Text] [Related]
8. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
[TBL] [Abstract][Full Text] [Related]
9. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Profiling in
Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
[No Abstract] [Full Text] [Related]
11. Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma.
Boukari F; Dugourd PM; Chassang M; Mondot L; Passeron T; Lacour JP; Montaudie H
Pigment Cell Melanoma Res; 2017 Mar; 30(2):262-264. PubMed ID: 27885826
[No Abstract] [Full Text] [Related]
12. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
13. MEK Retinopathy. Clinical case reports.
Rocha Cabrera P; Quijada Fumero E; Losada Castillo MJ; Abreu Reyes JA; Lorenzo Morales J
Arch Soc Esp Oftalmol (Engl Ed); 2018 Jan; 93(1):42-46. PubMed ID: 28506716
[TBL] [Abstract][Full Text] [Related]
14. Cobimetinib.
Signorelli J; Shah Gandhi A
Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
[TBL] [Abstract][Full Text] [Related]
15. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
Schmitt AM; Dumas L; Larkin J
Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
[TBL] [Abstract][Full Text] [Related]
17. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF
Lewis K; Hauschild A; Larkin J; Ribas A; Flaherty KT; McArthur GA; Dréno B; McKenna E; Zhu Q; Mun Y; Ascierto PA
Eur J Cancer; 2019 Jul; 116():45-55. PubMed ID: 31173962
[TBL] [Abstract][Full Text] [Related]
18. Cobimetinib and vemurafenib for the treatment of melanoma.
Boespflug A; Thomas L
Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF
Dréno B; Ascierto PA; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Bartley K; Karagiannis T; Chang I; Rooney I; Koralek DO; Larkin J; McArthur GA; Ribas A
Br J Cancer; 2018 Mar; 118(6):777-784. PubMed ID: 29438370
[TBL] [Abstract][Full Text] [Related]
20. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in
Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA
Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]